Member Info for ak_gabba

as at 10 February 2022, Biosynex's holding in the Company on a voting and capital basis is 3.0012% (2,119,627 shares)

as at 14 February 2022, Biosynex's holding in the Company on a voting and capital basis is 4.04% (2,855,959 shares)

no times are given but thats 3 trading days. They could well be over 5% right now if they are continuing their buying at a similar rate.

was reported 30-nov-21 that biosynex held 18.82% of theradiag's share capital

https://www.businesswire.com/news/home/20211129005813/en/THERADIAG-notes-the-acquisition-of-a-stake-in-its-capital-by-BIOSYNEX

was reported on 13-jan-22 that theradiag and biosynex have signed a distribution agreement

https://www.businesswire.com/news/home/20220112005904/en/Theradiag-Signing-of-a-Distribution-Agreement-with-BIOSYNEX-of-Their-AMPLIQUICK-SARS-CoV-2-PCR-Test

Could they be looking to something similar. Joint projects?

Exmex,

So we've figured out who larry10 is ;-) Larry Abensur

From the link that larry posted - http://novacyt.com/wp-content/uploads/2017/10/Admission-Document-Novacyt-18-October-2017.pdf

Page 36 - 19 Takeover code

Thats from 2017

From this link (2020) - https://uk.practicallaw.thomsonreuters.com/4-502-1646?transitionType=Default&contextData=(sc.Default)&firstPage=true#co_anchor_a746342

There is a section on mandatory offers which is 30% threshold

"The mandatory tender offer price must be at least the highest price paid by the bidder for securities of the target during the 12-month period preceding the crossing of the 30% threshold."

I think someone else alluded to this earlier, sorry I wasn't able to recall who from.

Thanks Larry10, that clears that up :)

Here are a couple of links regarding M&A activity

https://www.lexology.com/library/detail.aspx?g=64926d2e-cc8e-448b-bf7d-04579394b9f5

https://uk.practicallaw.thomsonreuters.com/4-502-1646?transitionType=Default&contextData=(sc.Default)&firstPage=true#co_anchor_a746342

SAGE have released a paper on viral evolution scenarios.

Here is the link which you can view the pdf from

https://www.gov.uk/government/publications/academics-viral-evolution-scenarios-10-february-2022

"In each scenario, it is assumed that a relatively stable, repeating pattern is reached over time (2-10 years) but it is likely that the transition to this will be highly dynamic and unpredictable. It may not be possible to know with confidence from what happens in the next 12-18 months which long-term pattern will emerge. "

"Surveillance, vaccines, therapeutics and testing will also have large impacts on outcomes"

"Access to testing has also been key for reducing transmission and is likely to impact the shape and duration of any future waves"

Well researched larry has provided these links on twitter (thank you!). Sharing them for the LSE/NCYT board to view.

The guidance for desktop review has been updated 10/2/22

https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/covid-19-test-approval-step-2-process-for-desktop-review

It's quite a read however here is a quick quote

"Where a test has already been validated by the Technologies Validation Group (TVG), the applicant can make a request to use the TVG data for the purposes of the CTDA application. Please email your request for data"

On the same day there were discussions in the lords

https://hansard.parliament.uk/Lords/2022-02-10/debates/FC1526E9-4CD9-49BB-9641-9558B57CDD2F/Covid-19LateralFlowTests

BIVDA have released a statement on 4/2/22

https://bivdanewsletter.com/membership-news/covid-19-desktop-validation-bivda-update-3/

"There have been a number of approvals which are set to be released imminently, so members should review the approved list which can be found at CTDA – approved-products
Over the Christmas period, most suppliers have provided the outstanding requested information and those are still in the evaluation stages"

Hopefully should see some (fingers crossed positive) movement for the outstanding tests from novacyt waiting on CTDA approval.

Exmex,

Here is the link with the atamis urls

https://bidstats.uk/tenders/2020/W47/739312011

Wilson, Not fully read it all but I'll have another go tomorrow. I thought some of the text indicated they were expecting to pay out more which would go into the following accounts. I couldn't find anything specific but not expecting to in a document like that.

Good luck with the football!

The dispute with the DHSC was first announced on 9th April 2021 (as if you needed reminded). The DHSC annual report has been released and I think the invoices in relation to the dispute will be referenced in the period ended 31st March 2021.

The report can be found here
https://www.gov.uk/government/publications/dhsc-annual-report-and-accounts-2020-to-2021

Its a big report and I've not been able to go through it all. Novacyt/PrimerDesign is NOT referenced and there is no direct correlation to the company and it's dispute. Please take a look for yourselves however here are a couple of things that caught my eye.

Page 182
"The Department has impaired NHS Test and Trace consumables totalling £195 million in
respect of items for which we have not currently identified a suitable use as described in
Note 8. These amounts represent the Department’s best estimate of the likely loss
which may crystalise and therefore become reportable as losses in future accounting
periods. Work is ongoing to ensure that the maximum possible value is recovered in
respect of these inventory items. These amounts are therefore not recorded as losses in
the current accounting period."

Page 205
"The Department is required under HM Treasury’s Managing Public Money to
include a full list of all losses across the Departmental Group. As set out on pages
181-182 of the Annual Report and Accounts, the Department has made
impairments of £8.97 billion on PPE and Test and Trace consumable inventory in
note 8 that have not yet been recognised as losses in Table 33. It is therefore highly
likely that further losses will be recognised in future years"

Note 8 is on page 256

Page 257

"NHS Test and Trace Consumables - £195 million relating to items for which we
have not currently identified a suitable use.

Other COVID-19 related equipment and consumables - £74 million, reflecting
impairment (£52 million) due to items being not suitable for their intended use
and £22 million relating to market price fluctuations."

Wilson,
Did you get that information from novacyt?

Neilriche,

From the initial R&D

"Development of CO-Prep™ to further automate and streamline the workflow process of the Company's near-patient PROmate® test"

Promate is on the temp list. Do you mean waiting on the promate tests receiving full desktop approval?

Neilrich3, Thats good news that it's still to be launched. I like your wish list Wilson.

I know it was picked up that CO-PREP trademark application was made a while ago. I think Dean/bladesharp picked up on this however I've spotted that it's now registered on 3-Dec-21. I wasn't aware (sorry if it's already been posted)

https://www.trademarkelite.com/uk/trademark/trademark-detail/UK00003684947/CO-PREP

Here are the trademarks I can find for primerdesign

https://www.trademarkelite.com/uk/trademark/trademark-owner/Primer%20Design%20Limited/1083622

ah OK didn't see your post on other threads. seen them now. i'm with you on that opinion re the II investment. I certainly can't get an answer from novacyt and I gather most other investors can't.

HarChris,
I can't answer your question directly however looking at their shareholders
https://sourcebiointernational.com/shareholder-information/
its chalk and cheese in comparison to novacyt. I think we are at +85% in non II / director holdings

Spot on Exmex. He received the first 1/3 of the LTIP with the the 2nd third due the following year and the final 3rd due the year after that. All payments are based on the employee still being employed on those dates so he won't receive the 2nd and 3rd tranche. That's how I read it

They responded with a statement which was part printed in the article.

TW is always looking for an angle but this article has been out for a while. He is clearly trying to short. His website that he looking for subscribers for is an interesting read to say the least! Wow lol

GM purchased stock not long after the drop in share price due to the announcement of the Pfizer vaccine. At that time the second contract with DHSC had begun and q16/q32 machines were being rolled out along with a lot of covid tests. The invoices at that time were going in and being paid almost as quickly. I'd imagine he thought at that time things would continue as such and phase 2 would be inevitable. Different times.

Cluslesshareboy, I am of the same opinion and have asked that question directly to novacyt.

Larry has posted this on twitter

https://twitter.com/Larry64450205/status/1487721713613877252

I'm unable to respond to his tweet however java and C# are programming languages and .NET can be used for developing applications. Also greenfield indicates a new project. Building something from scratch.

The 3 job posting are here on novacyts website.
http://novacyt.com/wp-content/uploads/2022/01/External-Advert-Software-Developer-Full-Stack.pdf
http://novacyt.com/wp-content/uploads/2022/01/External-Advert-Software-Developer-Java-X2.pdf
http://novacyt.com/wp-content/uploads/2022/01/External-Advert-Senior-Software-Developer-.NET_.pdf

The above roles appear to have been posted on 25/1/22

There is also this advert which many will have seen by now which was re-posted in Dec 2021.

http://novacyt.com/wp-content/uploads/2021/12/Advert-Firmware-Engineer.pdf

Certainly seems like they have a new project on the go and with it being software development located at Stokesley/IT-IS sounds plausible that they are trying to create software products to align with their instrumentations.